2015 American Transplant Congress
Forty-Seven Consecutive Simultaneous Liver-Kidney Transplants With Steroid Free Immunosuppression After Rabbit Antithymocyte Globulin Induction
Introduction: Utilization of rabbit antithymocyte globulin (RATG) induction as part of a steroid free immunosuppression protocol in orthotopic liver transplantation has gained wide acceptance in…2015 American Transplant Congress
DNA Methytransferase 1 Inhibition Potently Suppresses T Cell Cycle Progression Through Demethylation of the Key Cell Cycle Inhibitors p15, p16, p21 and p27
Background: Epigenetic mechanisms like acetylation and methylation have been gradually appreciated to play a critical role in the generation and function of various immune cells.…2015 American Transplant Congress
Induction of iNOS Expressed Macrophages from Mouse iPS cells That Contribute to Prolong Same iPS Cells-Derived Graft Survival in Allogeneic Recipients
BACKGROUND: Induced pluripotent stem cells (iPSCs)-technology provides new opportunities in regenerative medicine to generate grafts from donors for transplantation. However, particularly when allogeneic iPSCs are…2015 American Transplant Congress
Variants Associated With Tacrolimus Troughs in European American Kidney Transplant Recipients: A Genome Wide Association Study
Tacrolimus (tac) is dependent on CYP3A4/5 for metabolism. Variability in the metabolism is influenced by CYP3A5*3 alleles. This variant and clinical factors explain around 50%…2015 American Transplant Congress
Does Infection Impact On Tacrolimus Blood Levels in Kidney Transplant Recipients?
Background Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy in kidney transplant recipients. It is metabolized by members of the cytochrome p450 (CYP) 3A subfamily…2015 American Transplant Congress
Development and Validation of a Genotype Guided Tacrolimus Dosing Equation for African American (AA) Kidney Transplant Recipients
Tacrolimus (tac) has a strong exposure-response relationship with high inter-individual variability in troughs and dose. Tac dose requirements for AA patients are higher than Caucasians,…2015 American Transplant Congress
Calcineurin-Inhibitor Conversion to mTOR Inhibitor in Renal Transplant Recipients Leads to Worse Long Term Clinical Outcomes
We previously reported the short-term feasibility of Calcineurin-Inhibitor (CNI) elimination in kidney transplant recipients. We now report the long-term clinical impact on renal allograft function…2015 American Transplant Congress
Month 48 Follow-Up Results of HERAKLES Trial on Three Different Treatment Regimen and Switching Off Behaviour in De Novo Renal Transplant Patients
1Herakles Study Group, Germany; 2Novartis, Pharma, Germany; 3Herakles Study Group, Switzerland.
Aim: To compare switching off 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this prospective, open-label, randomized,…2015 American Transplant Congress
Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal Transplant Patients: Month 48 Follow-Up Results of the HERAKLES Trial
Aim: To compare safety and efficacy of 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this 1year,…2015 American Transplant Congress
Clinical and Pathologic Predictors of Response to Belatacept Conversion
Columbia Universtiy, New York.
INTRO: Calcineurin inhibitors have improved kidney transplant and recipient survival, their use has significant nephrotoxicity. Belatacept is a recently approved immunosuppressant that is not nephrotoxic…
American Transplant Congress abstracts